Normal view MARC view ISBD view

[Secondary structure of DNA from T4 and T6 phages]. [electronic resource]

By:

Mokul'skaia, T D

Contributor(s):

Producer: 19760430Description: 552-5 p. digitalISSN:

0026-8984

Subject(s):

In: Molekuliarnaia biologiia vol. 9

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: English Abstract; Journal Article

There are no comments on this title.

to post a comment.

Back to results

1621 New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
by Sahebkar, Amirhossein
1622 Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
by Bays, Harold E
1623 Spectrum of mutations in index patients with familial hypercholesterolemia in Singapore: Single center study.
by Pek, Sharon Li Ting
1624 Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis.
by Ding, Zufeng
1625 PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.
by Langsted, Anne
1626 Hyperhomocysteinemia and hyperandrogenemia share PCSK9-LDLR pathway to disrupt lipid homeostasis in PCOS.
by Mondal, Kalyani
1627 Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA.
by Bjune, Katrine
1628 Progress in finding pathogenic DNA copy number variations in dyslipidemia.
by Iacocca, Michael A
1629 Short‑term use of atorvastatin affects glucose homeostasis and suppresses the expression of LDL receptors in the pancreas of mice.
by Yu, Qi
1630 Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies.
by Cho, Leslie
1631 Real-world use of PCSK9 inhibitors: A single-center experience.
by Sarsam, Sinan
1632 Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.
by Nam, Chang-Wook
1633 Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
by Zaid, Ahmed
1634 Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
by Stein, Evan A
1635 Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro.
by Schroeder, Christina I
1636 Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).
by Canuel, Maryssa
1637 CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism.
by Dong, Bin
1638 PCSK9 inhibitors- A new age in lipid management?
by Grant, Peter J
1639 Modulation of cholesterol transport by maternal hypercholesterolemia in human full-term placenta.
by Zhang, Ran
1640 The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
by Ooi, Teik Chye